In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on ACADIA Pharmaceuticals (ACAD - Research Report), with a price target of $25.00. The company's shares closed yesterday at $16.62.Fein covers the Healthcare sector, focusing on stocks such as Sutro Biopharma, Amylyx Pharmaceuticals Inc, and ACADIA Pharmaceuticals. According to TipRanks, Fein has an average return of -7.2% and a 40.32% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $21.00 average price target, representing a 26.35% upside.
https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-acadia-pharmaceuticals-acad?utm_source=advfn.com&utm_medium=referral
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Acadia Pharmaceuticals Charts.
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Acadia Pharmaceuticals Charts.